Compugen

What Compugen does

Compugen Ltd. (NASDAQ: CGEN; TASE: CGEN.TA) is a clinical-stage cancer immunotherapy company headquartered in Holon, Israel, with U.S. operations in San Francisco. Founded in 1993, Compugen pioneered computational drug target discovery through its proprietary Unigen™ platform, which combines AI/ML predictive algorithms with deep scientific knowledge and cloud-based technology-agnostic tools to integrate multi-omics, single-cell RNA sequencing, and spatial omics data from multiple tumor types. The platform operates as a flexible-loop system in which outcomes from preclinical and clinical studies feed back into the proprietary knowledgebase to generate new target hypotheses. Compugen's discoveries include the TIGIT immune checkpoint (2009), the PVRIG immune checkpoint (2017), and the IL-18 binding protein pathway, yielding four clinical-stage programs: wholly-owned COM701 (anti-PVRIG) and COM902 (anti-TIGIT), plus licensed programs rilvegostomig (anti-PD-1/TIGIT bispecific with AstraZeneca) and GS-0321 (anti-IL-18BP with Gilead).

The company's wholly-owned pipeline targets the DNAM axis, addressing the 70–80% of cancer patients who do not respond to current PD-1/PD-L1 inhibitors, with a particular focus on ovarian, breast, endometrial, colorectal, lung, and biliary tract cancers. Its licensed programs are developed and commercialized by partners — AstraZeneca is advancing rilvegostomig across 11 Phase 3 trials, and Gilead is developing GS-0321 — while Compugen retains milestone and royalty rights. The business model is a B2B licensing model: the company does not commercialize products directly, instead generating revenue through upfront payments, development/regulatory milestone payments, and tiered royalties on future product sales from its pharmaceutical partners. To date, deals with AstraZeneca and Gilead have delivered over $135M in upfront and milestone payments and offer exposure to over $1.1B in additional potential milestones plus tiered royalties. As of March 31, 2026, the company held $134.9M in cash and cash equivalents, sufficient to fund operations into 2029, and operates with 51–100 employees.

Name

Compugen

Legal name

Compugen Ltd.

Website

https://cgen.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

Compugen is a clinical-stage cancer immunotherapy company that uses its proprietary Unigen™ AI/ML computational platform to discover novel immune checkpoint targets and license first-in-class drug candidates to large pharmaceutical partners including AstraZeneca and Gilead.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Drug Discovery

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Computational drug discovery
• Cancer immunotherapy
• Immune checkpoint inhibitors
• Antibody therapeutics
• Pharmaceutical licensing

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Partnership Milestone Payments: Compugen receives upfront payments and milestone payments upon achievement of development, regulatory, and commercial milestones from pharmaceutical partners. Examples include $65 million upfront from AstraZeneca for royalty monetization and potential $25 million additional milestone.
2. Royalty Revenue: Compugen is eligible for tiered royalties on future product sales. AstraZeneca partnership includes mid-single-digit royalties on rilvegostomig with potential peak royalty streams exceeding $200 million. Gilead partnership includes single-digit to low double-digit tiered royalties on worldwide net sales of GS-0321.
3. Collaboration Revenue: Revenue from collaboration arrangements including upfront payments and milestone achievements. Q1 2026 revenue was $2.2 million. Q4 2025 revenue was $67.3 million primarily from a $65 million upfront payment from AstraZeneca.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Compugen uses its proprietary AI/ML-powered Unigen™ computational platform to discover novel immune checkpoint drug targets and develop first-in-class cancer immunotherapy antibody candidates. The company licenses its discovered drug candidates to large pharmaceutical partners (AstraZeneca, Gilead Sciences) for clinical development and global commercialization, generating revenue through upfront payments, development and regulatory milestone payments, and tiered royalties on future product sales.

Product overview

Compugen is a clinical-stage cancer immunotherapy company that has developed Unigen™, an AI/ML-powered computational discovery platform for novel drug target identification. The company's product portfolio centers on immuno-oncology therapeutics targeting the DNAM axis and IL-18 pathway. Lead candidates include COM701 (anti-PVRIG antibody) and COM902 (anti-TIGIT antibody), both wholly-owned and in clinical development. Compugen has partnered with AstraZeneca on rilvegostomig (anti-PD1/TIGIT bispecific) and with Gilead on GS-0321 (anti-IL-18BP antibody). The company operates a flexible-loop discovery model where outcomes from preclinical and clinical trials enrich the proprietary knowledgebase for additional target discovery.

Differentiator

Problem solved

Functional benefit

Products and services

• COM701
• COM902
• Rilvegostomig
• GS-0321 (previously COM503)

Quantifiable outcome

• Peak sales potential of rilvegostomig exceeding $5 billion with Compugen eligible for mid-single-digit royalties
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Gilead SciencescoreOEM/ Whitelabel/ Licensing Partner · 1 January 2023In 2023, Compugen entered an exclusive license agreement with Gilead for anti-IL-18 binding protein antibodies including COM503 (now GS-0321). Compugen received $60 million upfront and $30 million upon IND clearance. Compugen is eligible for up to $758 million in additional development, regulatory, and commercial milestones, with total deal value up to $848 million plus single to low double-digit royalties on worldwide net sales. Gilead has sole right to develop and commercialize after Phase 1.
• AstraZenecacoreOEM/ Whitelabel/ Licensing Partner · 1 January 2018In 2018, Compugen entered an exclusive license agreement with AstraZeneca (through MedImmune) for the use of Compugen's monospecific antibodies that bind to TIGIT, including COM902, for development of bispecific and multispecific antibody products. AstraZeneca is responsible for all research, development, and commercial activities. Compugen received $40.5 million in upfront and milestone payments to date. Compugen is eligible for up to $200 million in development and regulatory milestones plus tiered royalties on future sales. The derived product rilvegostomig is in multiple Phase 3 trials. In December 2025, Compugen monetized a portion of future royalties for $65 million upfront with potential additional $25 million milestone.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Insitro: Insitro uses machine learning and high-throughput biology to discover and develop novel therapeutics, paralleling Compugen's AI/ML-enabled platform approach to drug target discovery and partnership-based development.
• Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery, directly comparable to Compugen's Unigen™ AI/ML-enabled biological target discovery approach. Both companies leverage proprietary computational platforms to identify novel drug targets and license programs to pharma partners.
• Exscientia: Exscientia is an AI-driven drug discovery company using machine learning and automation to design novel therapeutics, comparable to Compugen's Unigen™ platform in applying computational methods to drug discovery and partner-based commercialization.
• Arcus Biosciences: Arcus is a clinical-stage immuno-oncology company developing TIGIT-targeting antibodies (domvanalimab) and other checkpoint inhibitors, directly comparable to Compugen's TIGIT (COM902) and PVRIG (COM701) programs. Both companies target the DNAM axis for cancer immunotherapy.
• Mereo BioPharma: Mereo is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics including TIGIT-targeting antibodies (etigilimab), directly comparable to Compugen's COM902 TIGIT inhibitor in target selection and clinical-stage development.
• iTeos Therapeutics: iTeos developed anti-TIGIT antibody (eosvelimab) for cancer immunotherapy before being acquired by GSK, making it a directly comparable TIGIT-focused clinical-stage biotech with similar target overlap to Compugen's COM902 and PVRIG programs.
• Recursion Pharmaceuticals: Recursion uses AI/ML-driven high-throughput biology and chemistry to discover novel therapeutics, paralleling Compugen's computational target discovery model. Both are clinical-stage platform biotechs that partner with large pharma to advance discovered candidates.

Broad incumbents

• AbCellera Biologics: AbCellera is a clinical-stage antibody discovery platform company using AI/ML-enabled technology to discover therapeutic antibodies, comparable to Compugen's antibody discovery capabilities but with a broader technology stack including single-cell sequencing and protein engineering.
• MacroGenics: MacroGenics is a clinical-stage biotech developing antibody-based therapeutics for cancer, with multiple checkpoint inhibitor programs. Comparable to Compugen in therapeutic area (immuno-oncology) and clinical-stage antibody approach, though focused on broader targets beyond DNAM axis.

Emerging players

• CytomX Therapeutics: CytomX develops Probody® antibody-based cancer therapeutics using a conditional activation platform, partially comparable to Compugen's antibody-based immuno-oncology focus. Both are clinical-stage antibody platform companies with pharma partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CompugenLtd
• LinkedInlinkedin.com/company/compugen-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Compugen